EGFR and non-small cell lung carcinoma: Brain metastases occur in roughly one third of all EGFR-mutant NSCLC patients, with comparable frequency between classical EGFR and EGFR exon 20 insertion mutant subgroups, and therefore CNS activity is an important consideration for clinical utility [42,95].